American Society of Clinical Oncology (ASCO) 2022 Genitourinary Cancers Symposium – February 17-19, 2022 / San Francisco, CA and Virtual.
Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Avelumab first-line maintenance + best supportive care (BSC) vs BSC alone in Asian patients with advanced urothelial carcinoma: JAVELIN Bladder 100 subgroup analysis
Eto | Poster #486
PATRIOT II: an ambispective, observational, multicenter, 2-cohort study of avelumab first-line maintenance in locally advanced/metastatic urothelial carcinoma in the US
Grivas | Poster #TPS578
Disease management and frontline treatment of locally advanced or metastatic urothelial (la/mUC) carcinoma: the US physician PARADIGM study
Gupta | Poster #456
Criteria used to determine platinum eligibility and first-line (1L) treatment patterns among platinum-eligible (PE) and -ineligible (PI) patients with metastatic urothelial cancer (mUC) in France, Germany, Spain, Italy, and the UK (Eu5)
Milloy | Poster #457
Avelumab plus axitinib in advanced renal cell carcinoma (aRCC): 12-month interim results from a real-world observational study in the UK
Nathan | Poster #301
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term follow-up results from the JAVELIN Bladder 100 trial
Powles | Poster #487
Impact of COVID-19 on Cancer Caregivers: Results from the Global Carer Well-being Index
Turpin | Poster #460
This site is intended for US healthcare professionals only.
DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.
US-MULNP-00023 09/24
By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.
Help us direct you to the right information by selecting one of the following options: